MacroChem CEO to Host Open House Presentation at BioPartnering Europe Conference

Wellesley Hills, Massachusetts (ots/PRNewswire) -

- CEO to Provide Update on Company Developments

MacroChem's (OTC Bulletin Board: MACM) President and CEO, Robert
DeLuccia, will host an Open House Presentation at the 15th
Anniversary BioPartnering Europe Conference on Monday, October 8th
from 10:00 AM - 12:30 PM GMT, in the Fleming Room at the Queen
Elizabeth II Conference Centre in London, England. Mr. DeLuccia will
join other leading biopharmaceutical and diagnostic companies from
Europe, North America, and the rest of the world to host
two-and-a-half-hour interactive multimedia sessions on science and
technology, partnering strategies, developmental programs,
commercialization plans, product opportunities, and manufacturing
capabilities. Mr. DeLuccia will also present an overview of
MacroChem's progress and future business strategy in the Henry Moore
Room East at 3:45 PM GMT.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that
develops and seeks to commercialize pharmaceutical products.
Currently, our portfolio of proprietary product candidates is based
on our drug delivery technologies: SEPA(R), MacroDerm(TM) and
DermaPass(TM). Our lead product candidate is EcoNail(R), a topically
applied SEPA-based econazole lacquer for the treatment of
onychomycosis, a condition commonly known as nail fungus. Our other
clinical stage product candidate, Opterone(R), is a topically applied
SEPA-based testosterone cream designed to treat male hypogonadism. In
addition to EcoNail and Opterone, our pipeline of early-stage product
candidates is based on our SEPA, MacroDerm and DermaPass drug
delivery technologies. For more information visit our website,
http://www.macrochem.com. Recently, MacroChem announced it took a
step to broaden its product portfolio by acquiring an exclusive
option to license exclusive worldwide rights for drug uses of
pexiganan, a small peptide anti-infective for topical treatment of
patients with mild diabetic foot infection (DFI) from Genaera.

About BioPartnering Europe

BioPartnering Europe (BPE) was first held in London in 1993 as a
partnership between the U.S. Commercial Service and Technology Vision
Group LLC to bring about closer ties between American and European
biotechnology companies. From the beginning, BPE has attracted the
support of leading pharmaceutical, biotechnology, financial, and
service companies who have all contributed to making this one of the
leading independent partnering events in the world. BPE has a high
rate of sponsor retention, which signals its prominent role in the
annual conference calendar for many industry leaders. For more
information, please visit the website, http://techvision.com/bpe/

Forward-Looking Statements

With the exception of historical information contained in this
press release, the matters described herein are forward-looking
statements that involve risks and uncertainties. MacroChem's actual
results may differ significantly from the results discussed in the
forward-looking statements. Factors that might cause such a
difference include, but are not limited to, those discussed or
referred to in the section entitled "Risk Factors" in MacroChem's
Annual Report on Form 10-K, as well as those discussed elsewhere
therein, and include, without limitation, risks regarding product
development, the timing and results of clinical trials, the
regulatory approval process, capital requirements, financial
condition, patent protection, and dependence on third parties for
development and licensing arrangements. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date hereof. MacroChem undertakes no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise. For more information
visit our website, http://www.macrochem.com.

Contact:
MacroChem Corp.: Bernard Patriacca - VP/CFO
bpatriacca@macrochem.com
+1-781-489-7310
Investor Relations: The Investor Relations Group, Inc.
Christine Berni/ Joseph Triunfo, +1-212-825-3210
cberni@investorrelationsgroup.com
jtriunfo@investorrelationsgroup.com
Media:
Bill Douglass/ Michaela Heller, +1-212-825-3210
bdouglass@investorrelationsgroup.com
mheller@investorrelationsgroup.com
Web site: http://www.macrochem.com
http://techvision.com/bpe

ots Originaltext: MacroChem Corporation
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Bernard Patriacca, VP-CFO of MacroChem Corporation, +1-781-489-7310,
bpatriacca@macrochem.com; Investor Relations, Christine Berni,
cberni@investorrelationsgroup.com, or Joseph Triunfo,
jtriunfo@investorrelationsgroup.com, Media, Bill Douglass,
bdouglass@investorrelationsgroup.com, or Michaela Heller,
mheller@investorrelationsgroup.com, all of The Investor Relations
Group, Inc., for MacroChem Corporation, +1-212-825-3210